Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DTwP-Hepatitis B-Hib-IPV Vaccine in Indonesian Infants
NCT06690515Phase 2Not yet recruiting
- Sponsor
- Bio Farma
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of diphtheria + tetanus + whole-cell pertussis + hepatitis B + haemophilus influenzae type b + inactivated poliovirus in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by Bio Farma. Primary endpoints: Safety of the DTwP-Hepatitis B-Hib-IPV (Bio Farma) vaccine within 7 days after each dose and Immunogenicity of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
diphtheria + tetanus + whole-cell pertussis + hepatitis B + haemophilus influenzae type b + inactivated poliovirus
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT06690515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690515.